Background
==========

The accumulation of eosinophils in lung tissue is a hallmark of asthma, and it is believed that eosinophils play a crucial pathogenic role in allergic inflammation. Prostaglandin (PG) E~2~exerts anti-inflammatory and broncho-protective mechanisms in asthma, but the underlying mechanisms have remained unclear. We have shown previously that PGE~2~and the EP~2~receptor agonist butaprost inhibit eosinophil trafficking *in vitro* and *in vivo*.

Methods
=======

Human eosinophils were purified by negative magnetic selection from peripheral blood. Cell migration was determined in microBoyden chemotaxis chambers. Ca^2+^flux and expression of cell surface markers was recorded by flow cytometry. EP~4~receptor expression was demonstrated by immunostaining.

Results
=======

The chemotaxis of eosinophils towards eotaxin and C5a was attenuated by the EP~4~agonist ONO-AE1-329, and the EP~4~antagonists ONO-AE3-208 and GW627368x partially reversed the inhibitory effect of PGE~2~on eosinophil migration. ONO-AE1-329, and also PGE~2~, but not butaprost, inhibited the Ca^2+^flux and the production of reactive oxygen species in eosinophils. ONO-AE1-329 also inhibited eosinophil degranulation and the up-regulation of the adhesion molecule CD11b. Selective kinase inhibitors revealed that the inhibitory effect of EP~4~stimulation on eosinophil migration depended upon activation of phosphatidylinositol 3-kinase and protein kinase C, but not cAMP. Immunostaining showed that human eosinophils express EP~4~receptors and that EP~4~receptor expression in the murine lungs is prominent in airway epithelium, and after allergen challenge, in peribronchial infiltrating leukocytes.

Conclusion
==========

These data show that EP~4~receptor agonists potently inhibit eosinophil trafficking and activation, and might hence be a useful therapeutic option in eosinophilic diseases.
